GlassScriptPhysician profile
Virginia Rebollar
NPI 1285213470
$10,726.01
in general payments reported to CMS, 2019-2025
34 companies · $3,250 in 2025
The $3,250 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $406 · 2022: $2,018 · 2023: $2,114 · 2024: $2,938 · 2025: $3,250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,252 · Education: $27.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,252.46 |
| Education | $27.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,450.08 | 2021-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $1,787.25 | 2021-2025 | Nuplazid, Daybue |
| Abbvie INC. | $1,205.95 | 2022-2025 | |
| Amneal Pharmaceuticals LLC | $920.87 | 2021-2025 | Rytary, Crexont |
| Teva Pharmaceuticals USA, INC. | $845.04 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $710.24 | 2022-2025 | Gocovri |
| Kyowa Kirin, INC. | $519.34 | 2021-2025 | Nourianz |
| Ipsen Biopharmaceuticals, INC | $314.03 | 2022-2025 | Dysport |
| Otsuka America Pharmaceutical, INC. | $276.44 | 2023-2024 | Rexulti, Nuedexta |
| Avion Pharmaceuticals | $238.71 | 2022-2023 | Dhivy |
| Acorda Therapeutics, INC | $203.29 | 2021-2024 | Inbrija, Ampyra |
| Emd Serono, INC. | $140.56 | 2022-2023 | Mavenclad |
| Merz Pharmaceuticals, LLC | $108.48 | 2024-2025 | Xeomin |
| Lundbeck LLC | $85.91 | 2022-2023 | Vyepti |
| Lilly USA, LLC | $85.03 | 2023-2025 | Emgality, Kisunla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $74.10 | 2024-2025 | |
| Biogen, INC. | $72.48 | 2024 | Skyclarys |
| Avanir Pharmaceuticals, INC. | $71.79 | 2022 | |
| Sk Life Science, INC. | $67.98 | 2024 | |
| Medtronic, INC. | $67.25 | 2022-2024 | Percept PC Brainsense |
| Cala Health, INC. | $55.47 | 2024-2025 | Cala Kiq, Cala Kiq, Cala Trio |
| Impel Pharmaceuticals INC. | $54.90 | 2022-2023 | Trudhesa |
| Pfizer INC. | $52.50 | 2025 | |
| Ucb, INC. | $45.06 | 2022 | |
| Boston Scientific Corporation | $42.99 | 2024-2025 | General - Dbs |
| Ge Healthcare | $38.45 | 2022-2025 | |
| Grifols USA, LLC | $35.89 | 2023 | Gamunex-C |
| Sumitomo Pharma America, INC. | $32.49 | 2023 | Aptiom |
| Axsome Therapeutics, INC. | $28.10 | 2022 | |
| Adamas Pharmaceuticals, INC. | $22.40 | 2021 | |
| Mallinckrodt Hospital Products INC. | $21.12 | 2022 | |
| Janssen Biotech, INC. | $20.92 | 2025 | |
| Orphalan INC | $17.39 | 2024 | Cuvrior |
| Insightec,INC | $13.51 | 2025 | Exablate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Rebollar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.